DK0687251T3 - 1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister - Google Patents

1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister

Info

Publication number: DK0687251T3
Authority: DK; Denmark
Prior art keywords: vasopressin; ocytocin; dihydroindol; agonists; antagonists
Prior art date: 1993-12-24

Application number

DK95905164T

Other languages

Danish (da)

English (en)

Inventor

Claudine Serradeil-Legal

Jean Wagnon

Bernard Tonnerre

Alain Di Malta

Richard Roux

Marie-Sophie Amiel

Original Assignee

Sanofi Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-24

Filing date

1994-12-23

Publication date

2002-06-03

1994-12-23 Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo

2002-06-03 Application granted granted Critical

2002-06-03 Publication of DK0687251T3 publication Critical patent/DK0687251T3/da

Links

101800000989 Oxytocin Proteins 0.000 title abstract 2
102400000050 Oxytocin Human genes 0.000 title abstract 2
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 title abstract 2
108010004977 Vasopressins Proteins 0.000 title abstract 2
102000002852 Vasopressins Human genes 0.000 title abstract 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 title abstract 2
229960003726 vasopressin Drugs 0.000 title abstract 2
JYGFTBXVXVMTGB-HOSYLAQJSA-N 1,3-dihydroindol-2-one Chemical group N1C([13CH2]C2=CC=CC=C12)=O JYGFTBXVXVMTGB-HOSYLAQJSA-N 0.000 title 1
239000000556 agonist Substances 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK95905164T 1993-12-24 1994-12-23 1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister DK0687251T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9315638A FR2714378B1 (fr)	1993-12-24	1993-12-24	Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
PCT/FR1994/001528 WO1995018105A1 (fr)	1993-12-24	1994-12-23	Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine

Publications (1)

Publication Number	Publication Date
DK0687251T3 true DK0687251T3 (da)	2002-06-03

Family

ID=9454390

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95905164T DK0687251T3 (da)	1993-12-24	1994-12-23	1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister

Country Status (10)

Country	Link
US (2)	US5594023A (de)
EP (1)	EP0687251B1 (de)
JP (1)	JP3263081B2 (de)
AT (1)	ATE213727T1 (de)
DE (1)	DE69429984T2 (de)
DK (1)	DK0687251T3 (de)
ES (1)	ES2173172T3 (de)
FR (1)	FR2714378B1 (de)
PT (1)	PT687251E (de)
WO (1)	WO1995018105A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5612353A (en) *	1995-06-07	1997-03-18	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US5565483A (en) *	1995-06-07	1996-10-15	Bristol-Myers Squibb Company	3-substituted oxindole derivatives as potassium channel modulators
TW359669B (en) *	1995-12-15	1999-06-01	Otsuka Pharma Co Ltd	Benzazepine derivatives
AU4168999A (en) *	1998-06-19	2000-01-05	Wakamoto Pharmaceutical Co., Ltd.	Ocular tension lowering agents and phosphoric ester derivatives
FR2792834A1 (fr) *	1999-04-29	2000-11-03	Sanofi Sa	Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud
FR2804114B1 (fr) *	2000-01-25	2002-03-08	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804115B1 (fr) *	2000-01-25	2002-03-08	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr) *	2000-02-25	2002-08-23	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2807038B1 (fr) *	2000-04-03	2002-08-16	Sanofi Synthelabo	Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
US6673790B1 (en)	2000-04-03	2004-01-06	Sanofi-Synthelabo	Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
CN1440281A (zh) *	2000-05-03	2003-09-03	苏坎波公司	降眼压药
FR2810320B1 (fr) *	2000-06-19	2002-08-23	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2827604B1 (fr) *	2001-07-17	2003-09-19	Sanofi Synthelabo	Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
EP1504268A2 (de) *	2002-05-02	2005-02-09	Bayer HealthCare AG	Diagnostika und therapeutika für krankheiten, die mit dem oxytocin rezeptor (oxtr) assoziiert sind
US8580842B2 (en) *	2003-09-30	2013-11-12	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) *	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US7414052B2 (en)	2004-03-30	2008-08-19	Wyeth	Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en)	2004-03-30	2009-04-14	Wyeth	Phenylaminopropanol derivatives and methods of their use
DE102004033834A1 (de) *	2004-07-13	2006-02-02	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
FR2875499B1 (fr) *	2004-09-20	2006-10-27	Sanofi Aventis Sa	Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique
FR2880023B1 (fr)	2004-12-23	2007-02-23	Sanofi Aventis Sa	Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
US8030499B2 (en)	2005-01-28	2011-10-04	Taisho Pharmaceutical Co., Ltd.	1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
DE102005014904A1 (de)	2005-03-26	2007-02-01	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
CA2602194A1 (en) *	2005-03-24	2006-09-28	Abbott Gmbh & Co. Kg	Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
DE102005014936A1 (de) *	2005-03-24	2006-12-14	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
EP1957480A1 (de)	2005-12-02	2008-08-20	Abbott GmbH & Co. KG	Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
US8119676B2 (en) *	2006-08-26	2012-02-21	Abbott GmbH & Co. HG	Substituted benzimidazolone derivatives, medicaments comprising them and their use
DE102006040915A1 (de) *	2006-08-26	2008-03-20	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
US8486979B2 (en)	2006-12-12	2013-07-16	Abbvie Inc.	1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) *	2006-12-12	2008-07-10	Abbott Laboratories	Pharmaceutical compositions and their methods of use
UY30846A1 (es)	2006-12-30	2008-07-31	Abbott Gmbh & Amp	Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2008107399A1 (en)	2007-03-02	2008-09-12	Abbott Gmbh & Co. Kg	Substituted oxindole compounds
FR2920023B1 (fr) *	2007-08-16	2013-02-08	Sanofi Aventis	Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
CA2707669C (en) *	2007-12-07	2016-07-05	Wilfried Braje	5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
CA2707671C (en)	2007-12-07	2016-02-02	Abbott Gmbh & Co. Kg	5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
US8703774B2 (en)	2007-12-07	2014-04-22	AbbVie Deutschland GmbH & Co. KG	Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
WO2009071691A2 (de) *	2007-12-07	2009-06-11	Abbott Gmbh & Co. Kg	Oxindol-derivate und ihre verwendung als medikament
US8703775B2 (en)	2007-12-07	2014-04-22	AbbVie Deutschland GmbH & Co. KG	Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
SG188781A1 (en) *	2007-12-27	2013-04-30	Abbott Gmbh & Co Kg	Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
FR2927625B1 (fr) *	2008-02-19	2010-03-12	Sanofi Aventis	Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr)	2008-04-21	2010-05-14	Sanofi Aventis	Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
FR2941946B1 (fr)	2009-02-12	2011-03-25	Sanofi Aventis	Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
FR2941947B1 (fr)	2009-02-12	2011-03-25	Sanofi Aventis	Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
EP2435080A2 (de)	2009-05-29	2012-04-04	Abbott Laboratories	Pharmazeutische zusammensetzungen zur schmerzbehandlung
CN103380127B (zh)	2010-12-21	2016-08-10	拜耳知识产权有限责任公司	制备n-磺酰基取代的羟吲哚的方法
FR2974576B1 (fr)	2011-04-29	2013-07-19	Sanofi Aventis	Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
RU2743747C2 (ru) *	2016-01-20	2021-02-25	Кемосентрикс, Инк.	2-оксиндольные соединения
CA3121202A1 (en)	2018-11-30	2020-06-04	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3441570A (en) *	1966-01-20	1969-04-29	Parke Davis & Co	3-tertiary aminoalkylamino-3-phenyl oxindole compounds
GB1494340A (en) *	1974-12-03	1977-12-07	Wyeth John & Brother Ltd	Process for preparation of substituted n-phenylcarbamate esters
DE2553662A1 (de) *	1975-11-28	1977-06-08	Edgar Griebel	Pressvorrichtung fuer muelltonnen
FR2665441B1 (fr) *	1990-07-31	1992-12-04	Sanofi Sa	Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
FR2686878B1 (fr) *	1992-01-30	1995-06-30	Sanofi Elf	Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.

1993
- 1993-12-24 FR FR9315638A patent/FR2714378B1/fr not_active Expired - Fee Related
1994
- 1994-12-23 EP EP95905164A patent/EP0687251B1/de not_active Expired - Lifetime
- 1994-12-23 ES ES95905164T patent/ES2173172T3/es not_active Expired - Lifetime
- 1994-12-23 DE DE69429984T patent/DE69429984T2/de not_active Expired - Fee Related
- 1994-12-23 DK DK95905164T patent/DK0687251T3/da active
- 1994-12-23 AT AT95905164T patent/ATE213727T1/de not_active IP Right Cessation
- 1994-12-23 PT PT95905164T patent/PT687251E/pt unknown
- 1994-12-23 JP JP51781295A patent/JP3263081B2/ja not_active Expired - Fee Related
- 1994-12-23 WO PCT/FR1994/001528 patent/WO1995018105A1/fr not_active Ceased
- 1994-12-23 US US08/500,924 patent/US5594023A/en not_active Expired - Lifetime
1996
- 1996-04-30 US US08/640,080 patent/US5773612A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0687251B1 (de)	2002-02-27
US5594023A (en)	1997-01-14
FR2714378B1 (fr)	1996-03-15
DE69429984T2 (de)	2002-10-17
ES2173172T3 (es)	2002-10-16
JPH08507092A (ja)	1996-07-30
US5773612A (en)	1998-06-30
JP3263081B2 (ja)	2002-03-04
DE69429984D1 (de)	2002-04-04
PT687251E (pt)	2002-08-30
ATE213727T1 (de)	2002-03-15
FR2714378A1 (fr)	1995-06-30
EP0687251A1 (de)	1995-12-20
WO1995018105A1 (fr)	1995-07-06

Publication	Publication Date	Title
DK0687251T3 (da)	2002-06-03	1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister
DK0641328T3 (da)	2002-05-21	Broforbundne, azabicykliske derivater som substans P-antagonister
DK0889877T3 (da)	2001-10-01	Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
DE60120748D1 (de)	2006-07-27	3-substituierte oxindolderivate als beta-3-agonisten
NO960365D0 (no)	1996-01-29	Perhydroisoindolderivater som substans-P-antagonister
ATE269312T1 (de)	2004-07-15	N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
DE69932173D1 (de)	2006-08-10	Adenine-derivate
BR9303993A (pt)	1994-08-02	Composto, processo para preparar o mesmo e composição farmacêutica
DK0687268T3 (da)	1998-10-12	Spiroazacykliske derivater som substans P-antagonister
DK0771197T3 (da)	2003-06-23	Anvendelse af heterocykliske forbindelser som dopamin-D3-ligander
ATE212991T1 (de)	2002-02-15	Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
DK0773943T3 (da)	2002-03-04	Forbindelser, der er anvendelige som antiproliferative midler og garft-inhibitorer
FI943931A0 (fi)	1994-08-26	Indolijohdannaisia steroidi-5alfa-reduktaasin inhibiittoreina
DE69824756D1 (de)	2004-07-29	Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen,hypolipidämischen und antihypertensiven eigenschaften
DE69827614D1 (de)	2004-12-23	Chinoxalindionen
FI962322A0 (fi)	1996-06-03	(S,S,S)-N-(1-(2-karboksi-3-(N2-mesyylilysyyliamino)propyyli)1-syklopentyylikarbonyylityrosiinin kiteinen polymorfinen muoto
DK0765322T3 (da)	2001-10-22	Indolderivater som pro-drugs for 5-HT1-lignende receptoragonister